Thermo Fisher Scientific (TMO) has made notable progress in the biotech market. Their latest innovation is the introduction of the
Vulcan™ Automated Lab that aims to revolutionize
semiconductor analysis. This automated lab shows promising growth prospects for the semiconductor industry. They also saw good favorability amongst billionaires who view it as one of the
best diabetes stocks to invest in. Despite some dips in expectation for
demand recovery in 2025, Thermo Fisher still shows promise. This is highlighted by its lucrative acquisition of Solventum's
purification and filtration business for $4.1 billion. Further cementing their strong position, they successfully completed a $1B share repurchase and authorized another $4B. They've also expanded their biopharma services which could foster growth. In addition, Thermo Fisher managed to strike a critical
solar power agreement with X-ELIO that accelerates the company's goal for 100% renewable electricity in its European Operations.
Thermo Fisher Scientific TMO News Analytics from Fri, 28 Jun 2024 07:00:00 GMT to Thu, 20 Mar 2025 13:44:00 GMT -
Rating 7
- Innovation 8
- Information 6
- Rumor -5
